New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent
The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.
The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer. This story matters for Technology readers tracking tech. Reported by wired.com. Read the full original at the source link below.
Originally reported by wired.com. NewsTek.com curates and briefs the technology stories that matter. Our editorial policy →
Get the daily technology signal